Dr Todd McAllister | Executive Director
Amnion Foundation

Dr Todd McAllister, Executive Director, Amnion Foundation

Dr. McAllister is the co-founder and CEO of Cytograft Tissue Engineering, Inc., a regenerative medicine company developing cell-based therapies to repair and rebuild diseased tissues and organs without using synthetic biomaterials.  He has a B.S degree in Mechanical Engineering from the University of Washington, and a Ph.D. in Biomedical Engineering from the University of California, San Diego.  Dr. McAllister pioneered a novel business strategy that prioritized capital efficiency and research focus.  Over the span of 6 years, Cytograft was able to transition from inception to Phase II clinical trials, and is moving programs forward based on its proprietary platform, “TESA™,” Tissue Engineering by Self Assembly™. Cytograft is now one of the few Regenerative Medicine companies pursuing Phase IIb/III clinical trials.  The Company has a broad platform of therapeutic indications with vascular grafts, valve leaflets, covered stents, and dermal fillers that are under development.  
With more than two decades of experience, Dr. McAllister is a well-known thought leader in the field of Regenerative Medicine.  He is a frequent reviewer and contributor for high impact journals and is on the editorial board of the Journal of Biofabrication and on the Industry Committee for the Journal of Tissue Engineering. He is on the Executive Board for the International Cell Medicine Society.  Dr. McAllister has also sat as a reviewer or external advisory board member for AFIRM, NIH, and NSF EPSCOR grants.  He has sat on the advisory boards of several companies, including BioCardia, Lumen Therapeutics, Wolf Biosciences and others.  Dr. McAllister’s was also the co-Director of the Center for Regenerative Medicine at the St. Joseph’s Translational Research Institute in Atlanta, Georgia, where he oversaw a broader range of cell-based repair technologies.  


Cord Blood Day 2- Thursday 17th May 2018 @ 08:55

Chair’s opening remarks for Day 2

Cord Blood Day 2- Thursday 17th May 2018 @ 12:20

Broadening product offerings in family banking- new revenue opportunities or a distraction to clients?

  •     Plureon offers licenses to a branded placenta banking technology for private family banking
  •     Amnion is a nonprofit public stem cell bank that uses the same technology, and is focused on developing clinical applications for these cells
  •     Together, these platforms present an extension of the current cord blood banking model that may improve overall penetration rates 

back to speakers



Erica Baeta
+44 (0)207 092 1152


Jessica Robinson
t/ +44 (0)207 092 1150


Issa Mauthoor
+44 (0)207 092 1257